Quick Answer
Theravance Biopharma, Inc. reported Total Assets of $485.57 million for fiscal year 2025.
Theravance Biopharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $485.57M | +37.1% |
| 2024 | $354.16M | -7.3% |
| 2023 | $382.00M | -37.1% |
| 2022 | $607.40M | +62.1% |
| 2021 | $374.82M | -20.1% |
| 2020 | $469.06M | +14.7% |
| 2019 | $408.83M | -27.0% |
| 2018 | $560.24M | +26.9% |
| 2017 | $441.40M | -31.0% |
| 2016 | $639.25M | +113.0% |
| 2015 | $300.12M | -11.1% |
| 2014 | $337.77M | +1241.6% |
| 2013 | $25.18M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $415.46M | +16.7% | -2.5% |
| June 30, 2025 | $426.04M | +17.7% | +24.0% |
| March 31, 2025 | $343.58M | -7.5% | -3.0% |
| December 31, 2024 | $354.16M | -7.3% | -0.5% |
| September 30, 2024 | $356.11M | -13.9% | -1.6% |
| June 30, 2024 | $362.03M | -18.9% | -2.5% |
| March 31, 2024 | $371.31M | -31.1% | -2.8% |
| December 31, 2023 | $382.00M | -37.1% | -7.6% |
- Theravance Biopharma, Inc. showed an increase of +37.1% in Total Assets compared to the prior fiscal year.
- Over the 2013–2025 period, Theravance Biopharma, Inc.’s total assets has grown by 1828.6% (from $25.18 million to $485.57 million).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: